Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
- PMID: 15242866
- PMCID: PMC1754871
- DOI: 10.1136/ard.2004.024737
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
Abstract
Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
